Amneal Biosciences announced the launch of Meropenem for Injection, the generic version of AstraZeneca‘s Merrem.

Meropenem is a broad-spectrum carbapenem antibiotic indicated for susceptible infections including complicated skin and skin structure infections (SSSI), intraabdominal infections, and bacterial meningitis. 

Related Articles

The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. By penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, it leads to cell death. Meropenem readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding-protein (PBP) targets. 

Meropenem for Injection is available as 500mg and 1g per vial strengths in 10-count packages. 

For more information call (877) 835-5472 or visit